Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting epigenetic regulators to overcome drug resistance in cancers
Nan Wang, Ting Ma, Bin Yu
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 147

Showing 1-25 of 147 citing articles:

Tumor biomarkers for diagnosis, prognosis and targeted therapy
Yue Zhou, Lei Tao, Jiahao Qiu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 141
Epigenetic modification of m6A regulator proteins in cancer
Yumin Wang, Yan Wang, Harsh Patel, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 81
Targeting epigenetic and posttranslational modifications regulating ferroptosis for the treatment of diseases
Yumin Wang, Jing Hu, Shuang Wu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 72
Exploring the dynamic interplay between cancer stem cells and the tumor microenvironment: implications for novel therapeutic strategies
Yan-Ruide Li, Ying Fang, Zibai Lyu, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 64
Crossing epigenetic frontiers: the intersection of novel histone modifications and diseases
Weiyi Yao, Xinting Hu, Xin Wang
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 18
Drug resistance mechanisms and treatment strategies mediated by Ubiquitin-Specific Proteases (USPs) in cancers: new directions and therapeutic options
Hongli Gao, Zhuo Xi, Jingwei Dai, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 16
Writers, readers, and erasers RNA modifications and drug resistance in cancer
Di Chen, Xinyu Gu, Yeltai Nurzat, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 16
Key wound healing genes as diagnostic biomarkers and therapeutic targets in uterine corpus endometrial carcinoma: an integrated in silico and in vitro study
Feng Jiang, Sajjad Ahmad, Sumaira Kanwal, et al.
Hereditas (2025) Vol. 162, Iss. 1
Open Access | Times Cited: 2
Epigenetic Modulators as Therapeutic Agents in Cancer
Eshaan Patnaik, Chikezie O. Madu, Yi Lü
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 19, pp. 14964-14964
Open Access | Times Cited: 24
Promising role of protein arginine methyltransferases in overcoming anti-cancer drug resistance
Yongxia Zhu, Tong Xia, D Chen, et al.
Drug Resistance Updates (2023) Vol. 72, pp. 101016-101016
Open Access | Times Cited: 23
Anticancer drugs: How to select small molecule combinations?
Ruth Nussinov, Bengi Ruken Yavuz, Hyunbum Jang
Trends in Pharmacological Sciences (2024) Vol. 45, Iss. 6, pp. 503-519
Closed Access | Times Cited: 14
Epigenetic modification of ferroptosis by non-coding RNAs in cancer drug resistance
Hongquan Wang, Joshua S. Fleishman, Sihang Cheng, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 14
Restoration of epigenetic impairment in the skeletal muscle and chronic inflammation resolution as a therapeutic approach in sarcopenia
Gregory Livshits, Alexander Kalinkovich
Ageing Research Reviews (2024) Vol. 96, pp. 102267-102267
Closed Access | Times Cited: 13
Cancer Mutations Converge on a Collection of Protein Assemblies to Predict Resistance to Replication Stress
Xiaoyu Zhao, Akshat Singhal, Sungjoon Park, et al.
Cancer Discovery (2024) Vol. 14, Iss. 3, pp. 508-523
Open Access | Times Cited: 12
Cytokines and soluble mediators as architects of tumor microenvironment reprogramming in cancer therapy
Suling Xu, Qing-Qing Wang, Wenxue Ma
Cytokine & Growth Factor Reviews (2024) Vol. 76, pp. 12-21
Closed Access | Times Cited: 12
Tubulin alpha-1b chain was identified as a prognosis and immune biomarker in pan-cancer combing with experimental validation in breast cancer
Yiyang Wang, Yongxiang Li, Yubo Jing, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 12
Chromatin remodellers as therapeutic targets
Hayden A. Malone, Charles W.M. Roberts
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 9, pp. 661-681
Closed Access | Times Cited: 10
Targeting G9a/DNMT1 methyltransferase activity impedes IGF2-mediated survival in hepatoblastoma
Salih Demir, Negin Razizadeh, Émilie Indersie, et al.
Hepatology Communications (2024) Vol. 8, Iss. 2
Open Access | Times Cited: 9
The emerging roles of histone demethylases in cancers
Dali Tong, Ying Tang, Peng Zhong
Cancer and Metastasis Reviews (2024) Vol. 43, Iss. 2, pp. 795-821
Closed Access | Times Cited: 8
Sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-stage small cell lung cancer: a phase II clinical trial
Xiao Han, Jun Guo, Lingyu Li, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 8
LncRNA PVT1 links estrogen receptor alpha and the polycomb repressive complex 2 in suppression of pro-apoptotic genes in hormone-responsive breast cancer
Viola Melone, Domenico Palumbo, Luigi Palo, et al.
Cell Death and Disease (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1
Epigenetic Targets and Their Inhibitors in the Treatment of Idiopathic Pulmonary Fibrosis
Xiaohui Miao, Pan Liu, Yangyang Liu, et al.
European Journal of Medicinal Chemistry (2025) Vol. 289, pp. 117463-117463
Closed Access | Times Cited: 1
Organoids: An Emerging Precision Medicine Model for Prostate Cancer Research
Mohammad Waseem, Bi‐Dar Wang
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 1093-1093
Open Access | Times Cited: 7
The pharmacoepigenetic paradigm in cancer treatment
Belén Ocaña-Paredes, Sebastián Rivera-Orellana, David Ramírez, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 7
From Crypts to Cancer: A Holistic Perspective on Colorectal Carcinogenesis and Therapeutic Strategies
Ehsan Gharib, Gilles A. Robichaud
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 17, pp. 9463-9463
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top